Fig. 2.

Adjusted Cox regression survival curves by CYP3A4 promoter A–392G (usual MAP goal 102–107 mm Hg treatment group). Among men and women randomized to usual MAP treatment goal, there was not a significant difference in rate of reaching a target MAP of 107 mm Hg by A–392G genotypes (a; adjusted p = 0.77). Upon gender stratification, there was no difference among men (b; adjusted p = 0.82); however, women with A/A or A/G (compared to G/G) genotype were over 3 times more likely to reach a target MAP of 107 mm Hg (c; adjusted p = 0.02).